205 related articles for article (PubMed ID: 37314514)
1. Association of CDKN2A/B mutations, PD-1, and PD-L1 with the risk of acute lymphoblastic leukemia in children.
Ruan Y; Xie L; Zou A
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10841-10850. PubMed ID: 37314514
[TBL] [Abstract][Full Text] [Related]
2. Cyclin dependent kinase inhibitor 2A/B gene deletions are markers of poor prognosis in Indian children with acute lymphoblastic leukemia.
Agarwal M; Bakhshi S; Dwivedi SN; Kabra M; Shukla R; Seth R
Pediatr Blood Cancer; 2018 Jun; 65(6):e27001. PubMed ID: 29446543
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
4. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
5. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951.
Mirebeau D; Acquaviva C; Suciu S; Bertin R; Dastugue N; Robert A; Boutard P; Méchinaud F; Plouvier E; Otten J; Vilmer E; Cavé H;
Haematologica; 2006 Jul; 91(7):881-5. PubMed ID: 16818274
[TBL] [Abstract][Full Text] [Related]
7. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
9.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
Iacobucci I; Ferrari A; Lonetti A; Papayannidis C; Paoloni F; Trino S; Storlazzi CT; Ottaviani E; Cattina F; Impera L; Abbenante MC; Vignetti M; Vitale A; Potenza L; Paolini S; Soverini S; Pane F; Luppi M; Foà R; Baccarani M; Martinelli G
Clin Cancer Res; 2011 Dec; 17(23):7413-23. PubMed ID: 22134481
[TBL] [Abstract][Full Text] [Related]
11. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.
Yang J; Meng L; Yang Y; Gao H; Jiang H
Nucleosides Nucleotides Nucleic Acids; 2024; 43(3):230-248. PubMed ID: 37688463
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of CDKN2A/B deletions in acute lymphoblastic leukaemia: a meta-analysis.
Zhang W; Kuang P; Liu T
Ann Med; 2019 Feb; 51(1):28-40. PubMed ID: 30592434
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
[TBL] [Abstract][Full Text] [Related]
15. Confirmation of involvement of new variants at CDKN2A/B in pediatric acute lymphoblastic leukemia susceptibility in the Spanish population.
Gutierrez-Camino A; Martin-Guerrero I; Garcia de Andoin N; Sastre A; Carbone Bañeres A; Astigarraga I; Navajas A; Garcia-Orad A
PLoS One; 2017; 12(5):e0177421. PubMed ID: 28481918
[TBL] [Abstract][Full Text] [Related]
16. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
17. Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma.
Dogan S; Xu B; Rana S; Chen H; Ghossein RA; Berger MF; Ho AL; Katabi N
Mod Pathol; 2023 Jul; 36(7):100150. PubMed ID: 36841437
[TBL] [Abstract][Full Text] [Related]
18. CD274 (PD-L1), CDKN2A (p16), TP53, and EGFR immunohistochemical profile in primary, recurrent and metastatic vulvar cancer.
Lérias S; Esteves S; Silva F; Cunha M; Cochicho D; Martins L; Félix A
Mod Pathol; 2020 May; 33(5):893-904. PubMed ID: 31844270
[TBL] [Abstract][Full Text] [Related]
19. High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.
Dong Y; Zheng M; Wang X; Yu C; Qin T; Shen X
BMC Cancer; 2023 Nov; 23(1):1097. PubMed ID: 37950153
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
